

Supplemental Figure S3. NTX-301 effects in OC cells **(A)** mRNA expression levels of SCD measured by qRT-PCR in OVCAR5 cells treated with DMSO or NTX-301 (100nM, 3days) (n=3). **(B)** Western blot for DNMT1, SCD and β actin in FT190 cells treated with DMSO or NTX-301 (100nM, 1μM, 72 hours, n=2). **(C)** Western blot for SCD and beta actin in OVCAR5 cells stably transduced with shctrl or shSCD lentiviral particles. **(D)** Side scatter of FACS analysis of

OVCAR5 cells treated with DMSO or NTX-301 (100nM, 1μM, 48 hours) after staining with Annexin V-FITC and propidium iodide (PI). **(E)** Trypan blue staining shows the relative percentages of viable OVCAR5 cells after treatment with NTX-301 compared to DMSO treated cells (mean ± SD, n=3). **(F)** Quantification of the percentage of Annexin V-FITC positive (apoptotic) cells and Annexin V-FITC + propidium iodide (PI) positive (apoptotic and necrotic cells) treated with DMSO or NTX-301 (100nM, 1μM, 48 hours). (**G)** Side scatter of FACS analysis of OVCAR5 cells treated with DMSO or NTX-301 (100nM, 1μM, 72 hours) after staining with Annexin V-FITC and propidium iodide (PI). **(H)** Trypan blue staining shows the relative percentages of viable OVCAR5 cells after treatment with NTX-301 compared to DMSO treated cells (mean ± SD, n=3). **(I)** Quantification of the percentage of Annexin V-FITC positive (apoptotic) cells and Annexin V-FITC + propidium iodide (PI) positive (apoptotic and necrotic cells) treated with DMSO or NTX-301 (100nM, 1μM, 72 hours).